Market Place
Sourcing Support
AIM Immunotech Provides Routine Update On Annual Filings
13 Apr 2026 //
GLOBENEWSWIRE
AIM Immunotech Joins Virtual Investor Closing Bell Event
09 Apr 2026 //
GLOBENEWSWIRE
AIM ImmunoTech Announces Closing of its Rights Offering
06 Mar 2026 //
GLOBENEWSWIRE
AIM ImmunoTech Reminds Stockholders of March 3, 2026
27 Feb 2026 //
GLOBENEWSWIRE
AIM Immunotech Extends Rights Offering Subscription Period
25 Feb 2026 //
GLOBENEWSWIRE
AIM Immunotech Joins Virtual Investor Closing Bell Event
12 Feb 2026 //
GLOBENEWSWIRE
AIM ImmunoTech Announces Commencement of Rights Offering
12 Feb 2026 //
GLOBENEWSWIRE
AIM Immunotech Announces Commencement Of Rights Offering
11 Feb 2026 //
GLOBENEWSWIRE
AIM Immunotech Joins Webull Financial Webinar Series
06 Feb 2026 //
GLOBENEWSWIRE
AIM Immunotech Adjusts Key Dates And Terms For Rights Offering
27 Jan 2026 //
GLOBENEWSWIRE
AIM Immunotech Reveals Rights Offering Dates & Terms Related
23 Jan 2026 //
GLOBENEWSWIRE
AIM Immunotech Announces Stock Dividend
30 Dec 2025 //
GLOBENEWSWIRE
AIM Immunotech Joins Virtual Investor Closing Bell Series
01 Dec 2025 //
GLOBENEWSWIRE
AIM Immunotech To Attend The 2025 Maxim Growth Summit
20 Oct 2025 //
GLOBENEWSWIRE
Aim Immunotech Obtains Japan Patent For Cancer Therapy
25 Sep 2025 //
GLOBENEWSWIRE
AIM ImmunoTech Reveals Next CEO Corner Segment
21 Aug 2025 //
GLOBENEWSWIRE
AIM ImmunoTech Q2 2025 Financial Results and Corporate Update
15 Aug 2025 //
GLOBENEWSWIRE
Aim Immuno Tech to Present at Webull Financial Corporate Connect
14 Aug 2025 //
GLOBENEWSWIRE
AIM Immunotech Ampligen Featured at MSCI MSCS-2025 Symposium
06 Aug 2025 //
GLOBENEWSWIRE
AIM ImmunoTech Closes $8.0 Million Public Offering
31 Jul 2025 //
GLOBENEWSWIRE
AIM ImmunoTech Presents Potential of Private-Public Partnerships
02 Jul 2025 //
GLOBENEWSWIRE
AIM ImmunoTech Receives NYSE American Noncompliance Notice
20 Jun 2025 //
GLOBENEWSWIRE
AIM ImmunoTech`s Trading Suspension Lifted by NYSE American
12 Jun 2025 //
GLOBENEWSWIRE
AIM ImmunoTech Announces 1-for-100 Reverse Stock Split
11 Jun 2025 //
GLOBENEWSWIRE
AIM ImmunoTech Joins Virtual Investor "Top 5 for `25" Conference
11 Mar 2025 //
GLOBENEWSWIRE
AIM ImmunoTech Appoints David Chemerow as Independent Director
26 Feb 2025 //
GLOBENEWSWIRE
AIM ImmunoTech`s Plan Accepted by NYSE American for Compliance
26 Feb 2025 //
GLOBENEWSWIRE
AIM ImmunoTech Delays Offering Until 10-K Filing Completion
11 Feb 2025 //
GLOBENEWSWIRE
AIM ImmunoTech Releases Virtual Investor “What This Means” Segment
11 Feb 2025 //
GLOBENEWSWIRE
AIM ImmunoTech Reviews Progress & Sets Future Growth Goals
15 Jan 2025 //
GLOBENEWSWIRE
AIM ImmunoTech Elects Three Incumbent Board Members
17 Dec 2024 //
BUSINESSWIRE
AIM ImmunoTech Announces NYSE American Listing Noncompliance
17 Dec 2024 //
GLOBENEWSWIRE
AIM ImmunoTech Reminds Shareholders to Vote "FOR" Incumbent Board
16 Dec 2024 //
BUSINESSWIRE
Kellner Calls AIM Immunotech Stockholders To Vote Gold
13 Dec 2024 //
GLOBENEWSWIRE
Kellner Urges AIM Immunotech Vote Gold Proxy Card
13 Dec 2024 //
GLOBENEWSWIRE
AIM ImmunoTech Urges Shareholders To Vote "FOR" Incumbent Board
12 Dec 2024 //
BUSINESSWIRE
Ampligen Co-Inventor Joins AIM Scientific Advisory Board
10 Dec 2024 //
GLOBENEWSWIRE
Kellner Group Asks AIM Stockholders to Vote the Gold Card
06 Dec 2024 //
GLOBENEWSWIRE
AIM ImmunoTech Joins Virtual Investor KOL Connect Segment
06 Dec 2024 //
GLOBENEWSWIRE
ISS Recommends Vote "FOR" AIM ImmunoTech’s Board Nominees
05 Dec 2024 //
BUSINESSWIRE
AIM ImmunoTech Opposes Activist Group’s Nominees to Board
02 Dec 2024 //
BUSINESSWIRE
AIM ImmunoTech Announces Cash Conservation Plan
27 Nov 2024 //
BUSINESSWIRE
AIM ImmunoTech Refutes Activist Group’s False Claims
27 Nov 2024 //
BUSINESSWIRE
Kellner Group Urges AIM Immunotech Stockholders to Vote Gold Card
26 Nov 2024 //
GLOBENEWSWIRE
AIM ImmunoTech Presents Case for Re-Electing Directors
25 Nov 2024 //
BUSINESSWIRE
Kellner Group Urges AIM Immunotech Stockholders to Vote for Change
19 Nov 2024 //
GLOBENEWSWIRE
AIM ImmunoTech Publishes Breast Cancer Data From Roswell Park
19 Nov 2024 //
GLOBENEWSWIRE
AIM ImmunoTech Reports Q3 2024 Results, Corporate Update
15 Nov 2024 //
GLOBENEWSWIRE
AIM ImmunoTech to Discuss Q3 2024 Financials on Nov 15
06 Nov 2024 //
GLOBENEWSWIRE
AIM ImmunoTech to Participate in the 2024 Healthcare Virtual Summit
09 Oct 2024 //
GLOBENEWSWIRE
AIM ImmunoTech Announces $1.26 Million Registered Direct Offering
30 Sep 2024 //
GLOBENEWSWIRE
AIM ImmunoTech To Participate In Virtual Investor CEO Connect
27 Sep 2024 //
GLOBENEWSWIRE
AIM ImmunoTech`s Ampligen Study For Pancreatic Cancer Published
20 Aug 2024 //
GLOBENEWSWIRE
AIM ImmunoTech Reports Q2 2024 Results and Corporate Update
16 Aug 2024 //
GLOBENEWSWIRE
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
29 Jul 2024 //
GLOBENEWSWIRE
AIM Reports New Data On Ampligen`s Anti-Tumor Potential In Combo Therapy
24 Jul 2024 //
GLOBENEWSWIRE
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
03 Jul 2024 //
GLOBENEWSWIRE
AIM ImmunoTech to Participate in the Virtual Investor Pitch Conference
10 Jun 2024 //
GLOBENEWSWIRE
AIM ImmunoTech to Participate in the Virtual Investor Lunch Break Series
03 Jun 2024 //
GLOBENEWSWIRE
AIM ImmunoTech Announces Pricing of $2.0 Million Registered Direct Offering
31 May 2024 //
GLOBENEWSWIRE
